Clinical Trial ConcernsThe ACURATE IDE trial did not meet its non-inferiority endpoint, with higher rates of all-cause mortality, stroke, or rehospitalization in the neo2 arm compared to the control arm.
Growth ConcernsThere is a belief that BSX's organic growth may have reached a near-term peak, and there is concern that investors may increasingly worry about BSX's growth slowing as it laps its outstanding results and new PFA competitors enter the market.
Product WithdrawalBSX faced challenges when Varipulse was temporarily pulled from the US market, as investors anticipated significant market share losses to competitors.